Translate

Κυριακή 9 Ιουνίου 2019

BIOMARKERS, TRANSLATIONAL RESEARCH AND PRECISION MEDICINE
1O
Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer
N Vasan; P Razavi; J L Johnson; H Shao; E Reznik ...
Annals of Oncology, Volume 30, Issue Supplement_3, May 2019, mdz095, https://doi.org/10.1093/annonc/mdz095
Extract
Background: Activating mutations in PIK3CA, the gene coding for the catalytic subunit (p110α) of phosphoinositide-3-kinase (PI3K), are the most frequent oncogenic alterations in oestrogen receptor-positive (ER+) breast cancer and are also prevalent in other tumour types. PI3Kα inhibitors have recently been shown to be clinically active in ER+ breast cancers harbouring PIK3CA mutations. In early clinical trials we had observed that there was also a population of patients that displayed deep and prolonged clinical benefit. In one such patient, whose tumour we had fully genomically characterized, we detected the presence of double PIK3CA mutations in all metastatic sites and at...

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου

Translate